Compare GoPro Inc (GPRO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Mesoblast Limited — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Mesoblast Limited trades at $14.12 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 7.2× GoPro Inc's market cap, and GoPro Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Mesoblast Limited for 14 Days on average.
| GPRO | MESO | |
|---|---|---|
Market Cap | $243.50M | $1.75B |
Volume | 11,527,160 | 239,027 |
Sector | Technology | Health |
52-Week High | $2.35 | $20.96 |
52-Week Low | $0.58 | $13.19 |
Typical Hold Time | 45 Days | 14 Days |
Enterprise Value | $302.28M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, as the company faces significant financial challenges with negative net income margins and declining revenues. Despite recent product recognition for its MISSION 1 series, the stock has been volatile amid merger discussions with Starman Optical and influencer investment interest. Technical indicators show a bullish moving average signal but mixed oscillators, while fundamentals reveal persistent losses and cash burn.
The outlook remains highly speculative with a proposed $1.14 per share buyout offering a potential floor, but ongoing losses and competitive pressures pose substantial risks. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's turnaround prospects despite recent merger excitement.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
